Intra Vaginal Drug for Treatment of Polycystic Ovary Syndrome

1Samerjeet Kaur Chalal and Rupinder Kaur Sodhi


Polycystic ovary syndrome is the ordinary also the most controversial endocrinological syndrome affecting 4-10 percent of women. The Polycystic ovary syndrome PCOS is an endocrinopathy characterize by the augmented insulin resistance. The vaginal mucosal cavity is a viable, secure, highly attractive drug delivery site and highly versatile in drug absorption, metabolism, and removal. Logically, metformin was introduced to determine the extent to which hyperinsulinemia affects the condition's pathogenesis. Additionaly, sustained contact with the vaginal mucosa of a delivery system can be accomplished more effectively than at the other absorption sites such as intestinal mucosa or rectum. For the women with PCOS who are not overweight the Metformin is an active ovulation induction agent and provides few benefits for an ovulatory infertility such as clomiphene over other first-line therapies. Metformin should be given to women with the PCOS undergo in vitro fertilization to decrease their risk.of ovarian hyperstimulation syndrome. Limited evidence signifies that metformin may be a suitable alternative to oral contraceptive pill (OCP) in the treatment hyperandrogenic symptoms of PCOS, including hirsutism and acne.


Polycystic ovary syndrome (PCOS), Endocrinopathy, Metformin, Hirsutism, Insulin resistance, Clomiphene, hyperinsulinemia, In vitro fertilization

Paper Details
IssueIssue 4